Supernus Pharmaceuticals, Inc. has announced that the US Food and Drug Administration (FDA) has granted final approval to the company's Supplemental New Drug Applications (sNDAs) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults and adolescents aged ≥12 years. Supernus Pharmaceuticals, Inc. is headquartered in Rockville, MD.
Dosage/administration: The recommended dosage is 25 mg once daily, administered for the first week. Dosage should then be increased weekly by 25 mg increments to achieve desired clinical outcome. Capsules should be swallowed whole and should not be sprinkled on food, chewed, or crushed.
Adverse reactions: The most common adverse reactions at recommended dosing in adult and adolescent controlled migraine clinical trials were paresthesia, anorexia, weight decrease, difficulty with memory, taste perversion, upper respiratory tract infections, abdominal pain, diarrhea, hypoesthesia, and nausea.
Supernus receives final FDA approval for Trokendi XR® for migraine prophylaxis in adults and adolescents. [news release]. Rockville, MD: Supernus Pharmaceuticals, Inc. April 5, 2017. http://ir.supernus.com/releasedetail.cfm?ReleaseID=1020364. Accessed April 13, 2017.
This Week's Must Reads
Potential Limitations of Balance Confidence Scales, Int J MS Care; ePub 2018 Jan 24; Wood, Wajda, et al
Cognitive Phenotypes in MS and Targeted Treatments, J Neurology; ePub 2018 Jan 22; Leavitt, Tosto, et al
Demographic Characteristics in Persons with MS, J Int Neuropsychol Soc; 2018 Feb; Costa, et al
Mercy Evaluation of MS Appropriately Valid, Clin Neuropsychol; ePub 2018 Jan 23; Merz, et al
Walking Speed, Endurance Studied in Persons with MS, J Neurophysiol; ePub 2018 Jan 3; Almuklass, et al
Must Reads in FDA Actions
Riptide Aspiration System Receives FDA Clearance, Medtronic news release; 2018 Jan 16
FDA Approves Vercise Deep Brain Stimulation System, Boston Scientific news release; 2017 Dec 11
FDA Approves Repatha to Prevent Stroke, Heart Attack, Amgen news release; 2017 Dec 1
FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6